ABI
VIVS

Adamant Biomedical Investments’s VivoSim Labs VIVS Stock Holding History

Adamant Biomedical Investments’s Portfolio VIVS Stock Details VIVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-208
Closed -$319K – 104
2014
Q3 		$319K Buy
+208
New +$377K 0.08% 91

Other funds holding VIVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adamant Biomedical Investments's VIVS Position: Q4 2014 in Review

Adamant Biomedical Investments sold out of VivoSim Labs (VIVS) in Q4 2014, closing a stake of 208 shares — an estimated $319K sold.

Adamant Biomedical Investments first reported a position in VIVS in Q3 2014 and held it in 1 quarter. The position peaked at $319K in Q3 2014. 102 funds tracked by Wall St. Rank hold VIVS as of Q4 2014.

  • Adamant Biomedical Investments reported no remaining VivoSim Labs position as of Q4 2014 after selling out during the quarter.
  • Adamant Biomedical Investments sold 208 VivoSim Labs shares in Q4 2014, an estimated $319K.
  • Adamant Biomedical Investments first reported a position in VivoSim Labs in Q3 2014 and held it in 1 quarter.
  • Adamant Biomedical Investments's VivoSim Labs position peaked at $319K in Q3 2014.
  • 102 funds tracked by Wall St. Rank held VivoSim Labs as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.